Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 7Lymphoma, Large B-Cell, Diffuse 4Lymphoma 4Carcinoma, Non-Small-Cell Lung 4Burkitt Lymphoma 4Ovarian Neoplasms 3Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell 2Lung Neoplasms 2Head and Neck Neoplasms 2Xerostomia 1Thyroid Carcinoma, Anaplastic 1Thrombocytopenia 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Recurrence 1Prostatic Neoplasms 1Previously Treated Non Small Cell Lung Cancer 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pain 1Osteosarcoma 1Neutropenia 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Multiple Myeloma 1

Interventions

Dexamethasone 29Cyclophosphamide 21Rituximab 17Cytarabine 16Bortezomib 13Gemcitabine 12fludarabine 11Methotrexate 11Lenalidomide 10Filgrastim 10Vincristine 9Etoposide 9pomalidomide 8pembrolizumab 8Paclitaxel 8Azacitidine 8venetoclax 7carfilzomib 7Doxorubicin 7Docetaxel 7Cyclosporine 7Calcium Dobesilate 7Antilymphocyte Serum 7fludarabine phosphate 6Topotecan 6Temozolomide 6Radiotherapy 6Peripheral Blood Stem Cell Transplantation 6Mitoxantrone 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Recurrence × pegfilgrastim × Clear all
NCT02983097 2018-01-19

R²-DHAP

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Phase 1/2 Terminated
34 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡